HealthTech

JUL 31, 2026

Caristo Diagnostics’ CaRi-Heart® Coronary Inflammation Technology Authorized by U.S. FDA

HealthTech

JUL 29, 2026

Mirae raises $5.4M to turn patient texts into data for doctors

HealthTech

JUL 29, 2026

Vivid Dx Raises $15M to Help Hospitals Confront One of Modern Medicine’s Most Urgent Threats: Drug-Resistant Infections

Deep Tech

JUL 28, 2026

Wild Bioscience Ltd acquires F1 Seed Ltd to create Britain’s first independent precision-breeding wheat business.

HealthTech

JUL 23, 2026

Caristo Diagnostics Expands Executive Team, Naming David Vort Chief Commercial Officer and Chris Louk Chief Financial Officer

HealthTech

JUL 23, 2026

American Heart Association AI Assessment Lab Report Finds Ultromics’ EchoGo® Heart Failure May Identify HFpEF Earlier Than Standard Care

Deep Tech

JUL 23, 2026

Moa announces Series C funding-round

Life Sciences

JUL 16, 2026

Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies

Life Sciences

JUL 14, 2026

Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology

Life Sciences

JUL 02, 2026

The Next Era of Automated Super-Resolution Discovery

Life Sciences

JUN 29, 2026

Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis

Life Sciences

JUN 29, 2026

RQ Bio Announces $115 Million (£85.5 Million) Series A Financing to Advance Long-Acting Antibody Programme RQB01 for Full Season Influenza Prevention

...
Oxford researchers & innovators
Working on cutting-edge research? Let’s explore its potential together.
Start the conversation
Shareholders
Interested in owning shares in OSE?
Contact our team
Co-investors
Ready to back Oxford’s most exciting spinouts?
Explore opportunities

WORK WITH US

Oxford researchers & innovators

Want your research to have real-world impact?

We partner with researchers and innovators across Oxford, Harwell and Culham to explore commercial potential, co-create ventures and build companies.

Start the conversation

Investors

Interested in becoming an OSE shareholder?

We’ve raised over £850m from global investors keen to access Oxford’s diverse, world-leading science. Our shareholders don’t just back OSE – many also co-invest alongside us.

Contact our team

Co-investors

Looking to invest in Oxford’s most exciting companies?

We partner with specialist global investors to fund and scale our companies – from pre-seed to growth. Together, OSE and our co-investors have invested more than £3bn.

Explore opportunities
OSE Manager Limited, a wholly owned subsidiary of Oxford Science Enterprises plc, is authorised and regulated by the Financial Conduct Authority.